IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting.
Ontology highlight
ABSTRACT: Biliary tract cancers are anatomically distinct and genetically diverse tumors, evenly characterized by poor response to standard treatments and a bleak outlook. The advent of comprehensive genomic profiling using next-generation sequencing has unveiled a plethora of potentially actionable aberrations, changing the view of biliary tract cancers from an "orphan" to a "target-rich" disease. Recently, mutations in isocitrate dehydrogenase genes (IDH1/2) and fusions of the fibroblast growth factor receptor have emerged as the most amenable to molecularly targeted inhibition, with several compounds actively investigated in advanced-phase clinical trials. Specifically, the IDH1 inhibitor ivosidenib has been the first targeted agent to show a survival benefit in a randomized phase III trial of ch
SUBMITTER: Salati M
PROVIDER: S-EPMC7696955 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA